The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Secukinumab is efficacious and well-tolerated for patients with extensive moderate-to-severe scalp psoriasis.